Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review

被引：0
|
作者：
Mercedes Kile
Patcharaporn Sudchada
机构：
[1] University of Wisconsin-Madison,School of Pharmacy
[2] Naresuan University,Faculty of Pharmaceutical Sciences
来源：
International Urology and Nephrology | 2021年 / 53卷
关键词：
Chronic kidney disease; Anemia; Iron; ESA; Hypoxia-inducible factor prolyl hydroxylase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 290
页数：7
相关论文
共 50 条
  • [21] The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease
    Zhong, Hongzhen
    Zhou, Tianbiao
    Li, Hongyan
    Zhong, Zhiqing
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3003 - 3011
  • [22] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
  • [23] Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis
    Li, Jing
    Xie, Qiong-Hong
    You, Li
    Xu, Ning-Xin
    Hao, Chuan-Ming
    PHARMACOLOGICAL RESEARCH, 2021, 163
  • [24] Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients
    Nangaku, Masaomi
    Farag, Youssef M. K.
    DeGoma, Emil
    Luo, Wenli
    Vargo, Dennis
    Khawaja, Zeeshan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (07) : 1244 - 1252
  • [25] Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
    Akizawa, Tadao
    Macdougall, Iain C.
    Berns, Jeffrey S.
    Yamamoto, Hiroyasu
    Taguchi, Megumi
    Iekushi, Kazuma
    Bernhardt, Thomas
    NEPHRON, 2019, 143 (04) : 243 - 254
  • [26] Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia
    Nakanishi, Takeshi
    Kuragano, Takahiro
    CLINICAL KIDNEY JOURNAL, 2024, 17 (03)
  • [27] Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
    Macdougall, Iain C.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (05) : 399 - 405
  • [28] Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia
    Nakamura, Makiko
    Imamura, Teruhiko
    Sobajima, Mitsuo
    Kinugawa, Koichiro
    HEART AND VESSELS, 2023, 38 (02) : 284 - 290
  • [29] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
    Ogawa, Chie
    Tsuchiya, Ken
    Maeda, Kunimi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [30] Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia
    Makiko Nakamura
    Teruhiko Imamura
    Mitsuo Sobajima
    Koichiro Kinugawa
    Heart and Vessels, 2023, 38 (2) : 284 - 290
12345